Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...
Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...
Bengaluru: Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a ...
A complainant shared four third-party posts on X (formerly Twitter) and two online articles with the PMCPA to make the case ...
Separately, Moderna's drugs with somewhat more niche applications could drive the stock's price higher even in advance of their approval. In particular, its seven oncology drugs in mid-to-late ...
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...